

# J. B. Chemicals & Pharmaceuticals Limited

### Press Release

BSE Scrip Code: 506943 NSE Symbol: JBCHEPHARM

# J.B.Chemicals declares good set of numbers for 2010-11.

Mumbai, May 23, 2011: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its audited financial results for the financial year ended on March 31, 2011. The highlights of these results are as under:

## Stand-alone Results: Highlight for the year 2010-11:

(Rs. in crores)

Sales	787.58	Up 18% Y-o-Y
EBIDTA	171.08	Up 13% Y-o-Y
PAT	118.19	UP 17% Y-o-Y
EPS (Rs.)(FV Rs. 2)	14.00	UP 17% Y-o-Y

## Consolidated Results: Highlight for the year 2010-11:

(Rs. in crores)

Sales	871.68	Up 18% Y-o-Y
EBIDTA	195.50	Up 9% Y-o-Y
PAT	139.32	Up 17% Y-o-Y
EPS (Rs.)(FV Rs. 2)	16.50	Up 17% Y-o-Y

The overall performance of the company during the year, both at standalone and consolidated level has been satisfactory. The sales in all business units of the company fared well and the company consequently achieved growth of 18% in sales and similar growth in the bottom line. The rest of the world exports (other than Russia/CIS) particularly performed well with 24% growth in sales. This business unit, though has relatively small base, is on good growth trajectory. The domestic formulations business too fared well with 15% growth in sales, with focus products growing by 17%. During the year, the company launched Femident Division that caters to gynecology and dental products. As on March 11, the company had medical representative strength of 700 up from 544 on March 31 last year. The company remains committed and focused on domestic formulations business as it has good growth potential to offer for medium to long term. The company will make all necessary investments for growth in this business. On the other hand, the company's focused on all round efficiency

across all functions continues, and particularly stringent working capital management is reflected in the reducing interest cost.

During the quarter ended March 2011, the company's sales registered increase of 7%. The profit after interest and depreciation (but before mark to market provision) for the quarter at Rs. 24.10 crores was only marginally lower compared to profit of Rs. 24.40 cores in the same quarter last year. However, the profit before tax at Rs. 17.93 crores was affected due to mark to market provision on foreign exchange translation. During the quarter, the mark to market loss was Rs. 6.17 crores against gain of Rs. 6.79 crores in the same quarter last year.

#### Dividend:

The board of directors has recommended a dividend of Rs. 2 (100%) per equity share of face value of Rs. 2. This will absorb Rs. 19.66 crores including dividend distribution tax.

## **About JBCPL:**

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at <u>www.jbcpl.com</u>. For more details, you may contact:

M.C. Mehta Company Secretary-General Manager J. B. Chemicals & Pharmaceuticals Ltd. 91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.